#CLDX InsiderFinance's AI analysis caught a bearish Bear Put Spread at $39.30. It had run +22.67% in 7 trading days as CLDX slid to $31.10.
↘️ Block: downside put block, ~86x OI
➡️ Flow: $1.126M calls vs $664.4K puts
↗️ Sweep: fresh $40 Call, 3,111 contracts vs 51 OI
↘️ Block: downside put block, ~86x OI
➡️ Flow: $1.126M calls vs $664.4K puts
↗️ Sweep: fresh $40 Call, 3,111 contracts vs 51 OI
September 27, 2026 at 11:21 PM
#CLDX InsiderFinance's AI analysis caught a bearish Bear Put Spread at $39.30. It had run +22.67% in 7 trading days as CLDX slid to $31.10.
↘️ Block: downside put block, ~86x OI
➡️ Flow: $1.126M calls vs $664.4K puts
↗️ Sweep: fresh $40 Call, 3,111 contracts vs 51 OI
↘️ Block: downside put block, ~86x OI
➡️ Flow: $1.126M calls vs $664.4K puts
↗️ Sweep: fresh $40 Call, 3,111 contracts vs 51 OI
#BiotechHangout: Sam Fazeli, Brian Skorney, Matt Gline, Yaron Werber on market & policy: MFN & revenue sharing, IPOs (#$ETRA), Heidi Overton's FDA confirmation hearing, #$CMPX, stock moves: #$OMER, #$CGEM, #$MAZE, data: #$VRTX, #$CLDX, #$VKTX, #$AMGN, #$IONS, #$MRNA, #$ROIV, #$LXEO, Roche: bit.ly/3TjKnby
September 25, 2026 at 2:07 PM
#BiotechHangout: Sam Fazeli, Brian Skorney, Matt Gline, Yaron Werber on market & policy: MFN & revenue sharing, IPOs (#$ETRA), Heidi Overton's FDA confirmation hearing, #$CMPX, stock moves: #$OMER, #$CGEM, #$MAZE, data: #$VRTX, #$CLDX, #$VKTX, #$AMGN, #$IONS, #$MRNA, #$ROIV, #$LXEO, Roche: bit.ly/3TjKnby
6/6 Celldex's clinical calendar now have management's formal confidence anchoring the near-term narrative. Full: https://insider.wizybit.com/blog/post?slug=cldx-raises-full-year-guidance-on-stronger-than-expected-momentum-2026-09-24
September 24, 2026 at 1:25 PM
6/6 Celldex's clinical calendar now have management's formal confidence anchoring the near-term narrative. Full: https://insider.wizybit.com/blog/post?slug=cldx-raises-full-year-guidance-on-stronger-than-expected-momentum-2026-09-24
1/6 🧬 $CLDX Celldex Therapeutics has raised full-year guidance, InsiderWatch flagged the strong bullish signal in its 8-K filing on September 22. The biotech company's Item 8.01 disclosure reflects management's confidence in near-term execution and financial trajectory.
Read the full story
CLDX Raises Full-Year Guidance on Stronger-Than-Expected Momentum
InsiderWatch | insider.wizybit.com
insider.wizybit.com
September 24, 2026 at 1:25 PM
1/6 🧬 $CLDX Celldex Therapeutics has raised full-year guidance, InsiderWatch flagged the strong bullish signal in its 8-K filing on September 22. The biotech company's Item 8.01 disclosure reflects management's confidence in near-term execution and financial trajectory.
InsiderFinance's AI analysis featured this exact Bearish #CLDX Bear Put Spread at $39.3. Already +22.67% in 4 trading days.
↘️ Options: $3.32M puts vs $957.0K calls
↘️ Block: $38 Put 4,466 vs 3,039 OI, $3.02M
↘️ Options: $3.32M puts vs $957.0K calls
↘️ Block: $38 Put 4,466 vs 3,039 OI, $3.02M
September 23, 2026 at 10:20 PM
InsiderFinance's AI analysis featured this exact Bearish #CLDX Bear Put Spread at $39.3. Already +22.67% in 4 trading days.
↘️ Options: $3.32M puts vs $957.0K calls
↘️ Block: $38 Put 4,466 vs 3,039 OI, $3.02M
↘️ Options: $3.32M puts vs $957.0K calls
↘️ Block: $38 Put 4,466 vs 3,039 OI, $3.02M
$CLDX ripping 12.1% so far this session, 1,881,654 shares traded. watching this one, needs to base before Tapeboard flags it as a setup. not chas… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cldx-bk-dn-scanner&utm_term=scanner&s=CLDX
September 23, 2026 at 4:20 PM
$CLDX ripping 12.1% so far this session, 1,881,654 shares traded. watching this one, needs to base before Tapeboard flags it as a setup. not chas… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cldx-bk-dn-scanner&utm_term=scanner&s=CLDX
Celldex (#$CLDX): Both Phase 3 CSU Trials Meet Primary Endpoints, BLA Planned in 2027
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
September 23, 2026 at 3:50 PM
Celldex (#$CLDX): Both Phase 3 CSU Trials Meet Primary Endpoints, BLA Planned in 2027
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/celldex-ther...
Celldex Therapeutics $CLDX: Morgan Stanley raised its price target from $50.00 to $57.00 and maintained its Overweight rating.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
September 23, 2026 at 11:45 AM
Celldex Therapeutics $CLDX: Morgan Stanley raised its price target from $50.00 to $57.00 and maintained its Overweight rating.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
https://fundspec.ai/s/CLDX/analysts
Get a push the moment an analyst moves a price target.
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
September 22, 2026 at 9:35 PM
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
September 22, 2026 at 9:30 PM
#Healthcare Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous urticaria, a condition causing persistent hives, yet shares of CLDX fell roughly 28.6% ... Continue reading
$CLDX Session: regular. Trigger: breakout. Current price: $34.62. Moving down 8.6% so far this session. Session volume: 10,668,345 shares. Prior RT… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cldx-bk-dn-watch&utm_term=scanner&s=CLDX
September 22, 2026 at 7:13 PM
$CLDX Session: regular. Trigger: breakout. Current price: $34.62. Moving down 8.6% so far this session. Session volume: 10,668,345 shares. Prior RT… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cldx-bk-dn-watch&utm_term=scanner&s=CLDX
En la preapertura cayeron acciones como $CLDX, $DGX, $LH, $ECO, $BNC, $INSW, $KOS, $FRO, $CRML, $ANPA, $VLO, $MRNA, $ASST, $BSY, $MPC, $PBF, $APA, $ADPT, $STNG, $CRDO, $PSX, $SM, $LLY y más.
September 22, 2026 at 3:20 PM
En la preapertura cayeron acciones como $CLDX, $DGX, $LH, $ECO, $BNC, $INSW, $KOS, $FRO, $CRML, $ANPA, $VLO, $MRNA, $ASST, $BSY, $MPC, $PBF, $APA, $ADPT, $STNG, $CRDO, $PSX, $SM, $LLY y más.
#$CLDX Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals. notreload.xyz/xy/celldex-c...
Celldex CSU Readout Succeeds. Investors Wanted More
Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals.
notreload.xyz
September 22, 2026 at 12:23 PM
#$CLDX Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals. notreload.xyz/xy/celldex-c...
Premarket chaos decoded 🎰 #$CLDX -37% on GOOD Phase 3 data (buy rumor, sell news). #$VKTX +32% on obesity M&A frenzy. #$QNME +122%: a $22M pharma-to-'quantum' rebrand riding low-float momentum. Rule of premarket: price moves first, reasons later. 60M shares traded before your coffee. Most usually round
September 22, 2026 at 12:18 PM
Premarket chaos decoded 🎰 #$CLDX -37% on GOOD Phase 3 data (buy rumor, sell news). #$VKTX +32% on obesity M&A frenzy. #$QNME +122%: a $22M pharma-to-'quantum' rebrand riding low-float momentum. Rule of premarket: price moves first, reasons later. 60M shares traded before your coffee. Most usually round
🚨 JUST IN: $CLDX
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
September 22, 2026 at 11:10 AM
🚨 JUST IN: $CLDX
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
#SEC #stocks #investing #CLDX
🔗 secwatch.observer
🚨 $CLDX
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
SEC Filing: CLDX
Click to view the official SEC document.
www.sec.gov
September 22, 2026 at 11:10 AM
🚨 $CLDX
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorp...
BUY $CLDX (CLDX.O) [PharmaStudy] @ 10:58:00Z
September 22, 2026 at 10:58 AM
BUY $CLDX (CLDX.O) [PharmaStudy] @ 10:58:00Z
Sept 18, 2026: BioPharmCatalyst weekly watchlist—top biotech catalysts left this quarter. Key tickers: KOD, ACAD, KYTX, ORKA, CLDX. More insights in our daily newsletter. www.biopharmcatalyst.com/news/2026/se...
September 18, 2026 at 8:15 PM
Sept 18, 2026: BioPharmCatalyst weekly watchlist—top biotech catalysts left this quarter. Key tickers: KOD, ACAD, KYTX, ORKA, CLDX. More insights in our daily newsletter. www.biopharmcatalyst.com/news/2026/se...
🇺🇦 #NowPlaying on #KEXP's #VarietyMix
Cyndi Lauper:
🎵 Money Changes Everything
#CyndiLauper
▶️ 🪄 Automagic 🔊 show 📻 playlist on Spotify
▶️ Song/Cover on Bandcamp:
Cyndi Lauper - Money Changes Everything - [The! Art$ Mix CLDX 3.0], by Art$.Mix
track by Art$.Mix
theartsmixofi.bandcamp.com
August 20, 2026 at 10:12 AM
🇺🇦 #NowPlaying on #KEXP's #VarietyMix
Cyndi Lauper:
🎵 Money Changes Everything
#CyndiLauper
▶️ 🪄 Automagic 🔊 show 📻 playlist on Spotify
▶️ Song/Cover on Bandcamp:
Celldex Therapeutics ($CLDX) reported EPS of -0.94 beating estimate of -1.06 for Q2 2026. Revenue 22000.0 Vs 1.03912 Million expected.
https://fundspec.ai
Build custom AI trading models for CLDX with the FundSpec App!
https://fundspec.ai
Build custom AI trading models for CLDX with the FundSpec App!
August 6, 2026 at 10:00 PM
Celldex Therapeutics ($CLDX) reported EPS of -0.94 beating estimate of -1.06 for Q2 2026. Revenue 22000.0 Vs 1.03912 Million expected.
https://fundspec.ai
Build custom AI trading models for CLDX with the FundSpec App!
https://fundspec.ai
Build custom AI trading models for CLDX with the FundSpec App!
Celldex Loss Widens to $73.5M on Strategic Spending Ahead of Pivotal Barzolvolimab Data https://signalbloom.ai/news/CLDX/celldex-loss-widens-to-735m-on-strategic-spending-ahead-of-pivotal-barzolvolimab-data $CLDX #Earnings via @signalbloom.ai
August 6, 2026 at 8:05 PM
Celldex Loss Widens to $73.5M on Strategic Spending Ahead of Pivotal Barzolvolimab Data https://signalbloom.ai/news/CLDX/celldex-loss-widens-to-735m-on-strategic-spending-ahead-of-pivotal-barzolvolimab-data $CLDX #Earnings via @signalbloom.ai
🚨 $CLDX
On August 6, 2026, Celldex Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
On August 6, 2026, Celldex Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
SEC Filing: CLDX
Click to view the official SEC document.
www.sec.gov
August 6, 2026 at 8:02 PM
🚨 $CLDX
On August 6, 2026, Celldex Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
On August 6, 2026, Celldex Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
#CLDX Celldex Reports Second Quarter Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/CLDX/celldex-reports-second-quarter-financial-results-and-provides-j0ogdf5hklbm.html
https://www.stocktitan.net/news/CLDX/celldex-reports-second-quarter-financial-results-and-provides-j0ogdf5hklbm.html
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Celldex (NASDAQ:CLDX) reported second quarter 2026 results and a pipeline update. Cash, cash equivalents and marketable securities were $717.6 million at June 30, 2026, boosted by $323.8 million in net proceeds from an April underwritten public offering, with cash expected to fund operations through 2028. Q2 R&D expenses were $67.5 million and G&A expenses $13.1 million, leading to a net loss of $73.5 million, or ($0.94) per share.The Phase 3 barzolvolimab chronic spontaneous urticaria program (EMBARQ-CSU1/2) fully enrolled 1,939 patients six months ahead of guidance, with topline data expected Sept/Oct 2026 and a planned 2027 BLA. A Phase 3 barzolvolimab study in cold urticaria and symptomatic dermographism is ongoing, and Phase 2 atopic dermatitis data are expected in late 2026. The Phase 2 prurigo nodularis study did not meet endpoints and is being discontinued. First-in-human Phase 1 data for bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and good tolerability, supporting expansion into additional inflammatory indications.
www.stocktitan.net
August 6, 2026 at 8:01 PM
#CLDX Celldex Reports Second Quarter Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/CLDX/celldex-reports-second-quarter-financial-results-and-provides-j0ogdf5hklbm.html
https://www.stocktitan.net/news/CLDX/celldex-reports-second-quarter-financial-results-and-provides-j0ogdf5hklbm.html